I'm on three-month shots of Eligard plus daily Apalutamide/Erleada. Undetectable PSA after three months of adding Erleada. Side effects negligible. I'm looking forward to seeing future results as the 44 month ones are impressive and confidence building.
My father has been on Erleada since Sept. 2019 and his PSA as of last month is still trending downward (currently at 0.02). Side effects have been non-existent for him. Hope for many more months/years for him and yourself!
A couple of good sections from the video and transcript:
"And I think this is the most interesting part of this project or paper and I think the most valuable information for the clinicians as well as patients. After adjusting for crossover using the standardized tool in a pre-specified manner, the risk reduction was further improved. The reduction of risk in death was improved now to 48%, almost a 50% reduced risk of that with apalutamide. And I think this is unprecedented. We have never seen this level of improvement in overall survival with almost a 50% reduced risk of death, precisely 48% with any agent in the context of metastatic castration-sensitive prostate cancer. And I think this is really fantastic news for our patients."
"I would like to add that novel androgen receptors blockers such as apalutamide or enzalutamide definitely have an edge over docetaxel chemotherapy or abiraterone plus prednisone in my view because they do not require frequent monitoring of electrolytes or they do not require patients to come to the hospital quite as often for an infusion in the context of docetaxel or electrolyte checks, blood pressure checks in the context of abiraterone. This makes it even more pertinent during the pandemic over the last one and a half years. I have personally prescribed apalutamide for my patients and I have told them that I will see you three months after. Did we have this luxury just two or three years ago?
So I think we have these highly well-tolerated drugs, these are oral pills that give a lot of independence to my patients as far as their own care is concerned. They can go home with some bottles of pills and then they control their lives so much better than when they were receiving chemotherapy with docetaxel or abiraterone with prednisone. So I think this would be my viewpoint. I'm not saying necessarily it should be the viewpoint of everyone, but I think these agents, novel androgen receptor blockers, allow my patients to have a much better quality of life, much better survival. And there is no reason for us to not advocate for upfront intensification of therapy in our patients with newly diagnosed metastatic castration-sensitive prostate cancer.
Started Eligard/Erleada Nov of 19……last 3 PSA test was 0.00. I was a 4+3=7 Gleason and 22.3 PSA. Sep of 16 had RP and prostate bed radiation in Jan of 17. Never got below a .5 PSA. 3 lymph node Mets on Nov of 19 Axumin scan did not show up on Dec of 20 bone/ct scan.
It’s really good news for those who are still castrate sensitive. Men in this position should go for it! $16,000 a month retail price be damned!
I am on a trial with apalutamide and abiraterone. As a castrate-resistant patient it will be interesting to see how this goes. I believe that I am close to “progression” due to rising PSA and increased met sizes but must wait a while to see what the July scans say.
I'm getting my monthly supply of Erleada for free -- delivered to the door -- so I couldn't be happier. Once I started on that drug I added metformin (500mg in a.m. and 500mg at dinner) and atorvastatin (20mg once daily) to offset the negative side effects. Works for me. I also take a number of supplements including turkey tail mushroom (to address stem cell movement and colonization): sciencedaily.com/releases/2... + penntoday.upenn.edu/news/co... . YMMV.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.